Saudi Arabia records 220 new COVID-19 cases, 13 deaths

Saudi Arabia records 220 new COVID-19 cases, 13 deaths
Of the new cases, 55 were recorded in Riyadh, 28 in Jeddah and 15 in Madinah, the Kingdom's health ministry said. (AFP/File Photo)
Short Url
Updated 28 November 2020

Saudi Arabia records 220 new COVID-19 cases, 13 deaths

Saudi Arabia records 220 new COVID-19 cases, 13 deaths
  • The new deaths raise the Kingdom’s COVID-19 death toll to 5,870

LONDON: Saudi Arabia confirmed 220 new cases of the coronavirus disease (COVID-19) and 13 new deaths over the past 24 hours, according to the Kingdom’s health ministry.

Of the new cases, 55 were recorded in Riyadh, 28 in Jeddah and 15 in Madinah, the ministry added in its daily breakdown, taking the running total to 356,911.

The new deaths raise the Kingdom’s COVID-19 death toll to 5,870.

Meanwhile, a further 401 people who had previously tested positive have recovered, raising the total recoveries to 346,023.


Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam
Updated 19 min 10 sec ago

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour is an assistant professor of epidemiology at the Institute for Research and Medical Consultations (IRMC), affiliated with Imam Abdulrahman Bin Faisal University (IAU), in Dammam.

Al-Mansour led many research projects from conception to execution at the department of epidemic diseases research at IAU and supervised graduate students and junior scientists.

She acted as the principal investigator on a number of key research projects related to the development of nucleic acid-based vaccines, the establishment of several virus bioinformatics databases and analysis resources, and virus immune monitoring studies.

Al-Mansour believes that investment in vaccine research is an important step to combat epidemics and pandemics caused by new viruses. This is followed by the localization of the manufacturing of vaccines and biological medicines.

She served as a Ph.D. researcher at the nucleic acid vaccine (NAV) lab at the University of Massachusetts, US, where she conducted rigorous research in the design, generation, and testing of DNA vaccines expressing HA’s of influenza (H1N1) strains.

Al-Mansour’s research is focused on cutting-edge technology to develop prophylactic vaccines against emerging and re-emerging viruses.

She earned a Ph.D. in biomedical engineering and biotechnology from the University of Massachusetts, US, and a master’s degree in clinical laboratory sciences from the University of Rhode Island, US.

Al-Mansour received her bachelor’s in medical laboratory technology from IAU.

She is also an academic member at the European Virus Bioinformatics Center (EVBC), Germany, and a member at the International Society for Global health (ISoGH), in the UK.